Noble Capital analyst Robert LeBoyer raised the firm’s price target on GeoVax Labs to $10 from $6 and keeps an Outperform rating on the shares based on recent progress, including the company recently having announced a DARPA grant for CM04S1 and its Phase 2 plans for Gedeptin in HNSCC. On August 14, WHO declared Mpox to be a “public health emergency of international concern”, or PHEIC, and the Mpox news has highlighted recent advances in GeoVax’s manufacturing platform and its modified vaccinia ankara, or MVA, based vaccine for smallpox and Mpox, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOVX:
- Siga slides, GeoVax jumps after mpox study shows limited effectiveness
- GeoVax to Present at the Emerging Growth Conference on August 21, 2024
- GeoVax shares jump after after Siga mpox study failure
- Siga, GeoVax rally after WHO declares mpox global emergency
- GeoVax Labs appoints Lambe to Scientific Advisory Board